Heimdall Insights

Global Heart Failure Drugs Market

Sizing, Segmentation, & Growth Forecast (2025-2030)

Last updated: August 2026

Report Scope: The downloadable datasheet contains market sizes in USD for the period 2025-30.

Market Breakdown: Sizes and growth rates are broken down by geography and market segment (see below for details).

1. Summary

The Global Heart Failure Drugs Market was valued at $14.8 bn. in 2025. During the forecast period 2025-2030, it is expected to grow at 10.8% CAGR, to an estimated market size of $24.7 bn. in 2030. A detailed breakdown by segment and geography is provided in the downloadable datasheet.

2. Market Definition

The global heart failure drugs market includes pharmaceutical therapies specifically indicated for the management of congestive heart failure (CHF), including Heart Failure with Reduced Ejection Fraction (HFrEF) and Heart Failure with Preserved Ejection Fraction (HFpEF). The scope covers drug classes such as ARNIs, SGLT2 inhibitors, beta-blockers, ACE inhibitors, ARBs, and diuretics, while excluding surgical devices and heart transplants.

3. Trends & Demand Drivers

Several key trends are expected to significantly impact the Heart Failure Drugs Market in the period 2025-30:

4. Market Breakdown

The downloadable datasheet breaks market sizes and growth rates (CAGRs) down into the following geographies and segments:

Geographies

  • North America
  • Europe
  • Asia-Pacific
  • Rest of World

Segments

  • ARNIs
  • Beta-blockers
  • SGLT2 Inhibitors
  • ACE Inhibitors & ARBs
  • Others (Diuretics, MRAs, etc.)